BioSpace News Archive

If replicated in humans, this technology could prolong organ health during major surgeries and improve the availability of donor organs.

Pfizer announced Monday that it is acquiring the hematology-focused company for $5.4 billion in order to bolster its presence in the multi-billion dollar rare disease market.

Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.

The Inflation Reduction Act, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives.

Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT, its lead candidate, can strongly reduce symptom severity in schizophrenia patients.

A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.

Industry executives often lament the fact that clinical trials take a long time to complete and often fail. BioSpace spoke with Tufts’ Ken Getz about possible reasons and solutions.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2022.

POXEL SA announced that is has entered into an agreement with IPF to restructure its existing debt facility and an equity-linked financing for up to EUR 6 million with IRIS.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global liposome drug delivery market was valued at US$ 3.6 Bn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027.